CLINICAL_TRIALS
trial_result
· 2009-06-05
Clinical Trial Update: Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL [Phase 1]
Summary
A Phase 1 dose-escalation study of CNF2024 (BIIB021) in chronic lymphocytic leukemia has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: B-Cell Chronic Lymphocytic Leukemia | Phase 1 | Status: TERMINATED